Inhibition of the low density lipoprotein-induced vascular smooth muscle cell growth by PPARγ ligands

Drug News and Perspectives

Volumn 15, Issue 1, 2002, Pages 5-9

  Gouni Berthold, Ioanna ^a   Sachinidis, Agapios ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HORMONE RECEPTOR; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; INSULIN SENSITIVITY; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0036205029     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.1.660509     Document Type: Review

References (71)

1. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
2. Peroxisome proliferator-activated receptors, orphans with ligands and functions
3. Expression of peroxisome prolifirator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells
4. Expression and function of PPARgamma in rat and human vascular smooth muscle cells
5. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
6. Effect of troglitazzone in insulin-treated patients with type II diabetes mellitus
7. On par with PPARs
8. The hormone resistin links obesity to diabetes
9. Improvement in glucose tolerance and insulin resistance in obese subjects treated with traglitazone
10. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
11. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
12. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
13. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
14. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
15. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
16. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
17. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
18. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth
19. Perspectives in diabetes: The mystery of diabetes and atherosclerosis
20. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma)
21. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
22. A receptor-mediated pathway for cholesterol homeostasis
23. Lipoproteins increase growth and mitogen stimulated arterial smooth muscle cell
24. The growth-promoting effect of low-density lipoprotein may be mediated by a pertussis toxin-sensitive mitogen-activated protein kinase pathway
25. Cholesterol enhances platelet-derived growth factor-BB-induced [Ca2+]i and DNA synthesis in rat aortic smooth muscle cells
26. Novel cellular activities for low-density lipoprotein in vascular smooth muscle cells
27. Low density lipoprotein enhances the thrombin-induced growth of vascular smooth muscle cells
28. Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells
29. Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum
30. Minimally modified low density lipoproteins induce aortic smooth muscle cell proliferation via the activation of mitogen activated protein kinase
31. Native low-density lipoprotein (LDL) induces the expression of the early-growth response gene-I in human umbilical arterial endothelial cells
32. Oxidised lipoproteins in atherosclerosis and thrombosis
33. Oxidised low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture
34. Contrary effects of lightly and strongly oxidised LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts
35. Enzymatically degraded, nonoxidised LDL induces human vascular smooth muscle cell,foam cell transformation and proliferation
36. Vascular smooth muscle proliferation: Synergistic interaction between serotonin and low density lipoproteins
37. Synergistic interaction between thromboxane A2 and mildly oxidised low density lipoprotein on vascular smooth muscle cell proliferation
38. Activation of EGF receptor by oxidised LDL
39. Oxidised LDL induces production of platelet derived growth factor AA from aortic smooth muscle cells
40. Native and oxidized LDL enhances production of PDGF-AA and the surface expression of PDGF receptors in cultured human smooth muscle cells
41. Induction of platelet-derived growth factor chain A gene expression in human smooth muscle cells by oxidized low density lipoproteins
42. The pathogenesis of atherosclerosis: A perspective for the 1990s
43. Lipoproteins induce expression of the early growth response gene-I in vascular smooth muscle cells from rat
44. Intracellular free calcium concentration and thromboxane A2 formation of vascular smooth muscle cells are influenced by fish oil and n-3 eicosapentaenoic acid
45. Thromboxane A2 and vascular smooth muscle cell proliferation
46. Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells
47. Replication of smooth muscle cells in vascular disease
48. PPARgamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
49. 1 to S transition in vascular smooth muscle cells
50. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Wafl/Cip 1), during adipogenesis
51. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
52. Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells
53. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
54. Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes
55. 2+ mobilization and cell proliferation in vascular smooth muscle cells
56. Differential regulation by troglitazone of plasminogen activator inhibitor type I in human hepatic and vascular cells
57. Effect of troglitazone on fibrinolysis and activated coagulation in patients with noninsulin-dependent diabetes mellitus
58. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
59. Effects of a thiazolidinedione compound on body fat distribution of patients with type 2 diabetes
60. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
61. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
62. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial
63. Nuclear factor-kB suppressive and inhibitor-kB stimulatory effects of troglitazone in obese patients with type 2 diabetes: Evidence of an antiinflammatory action
64. Suppression of nuclear factor-kB (NFkB) and stimulation of inhibitor kB (lkB) by troglitazone: Evidence,for anti-inflammatory effect and a potential anti-atherosclerotic effect in the obese
65. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilation in obese subjects
66. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPARgamma), GW7845, inhibits rat mammary carcinogenesis
67. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids
68. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer
69. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
70. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
71. Activation of the nuclear receptor PPARgamma enhance colon polyp formation